Drawing for SOLUPRIME

USPTO serial 99650302

SOLUPRIME

Reviewed by CopyMark Law Group

Status 653
Filing date
Status date
Registration date
—
Examiner
OGUNFEMI, RASHEEDAT
Law office
TMO LAW OFFICE 131

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with SOLUPRIME?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Andrew D. Skale

Andrew D. Skale Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.3580 Carmel Mountain RoadSuite 300San Diego, CA 92130

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of certain oncology and autoimmune disorders; stem cells for medical purposes; living cells for medical useACTIVE—
009Scientific apparatus and instruments, including scientific apparatus and instruments in the nature of instruments for use with transfection technologies and to facilitate gene editing and cell therapies for the transfer of biological molecules into living cells; measuring apparatus and instruments for use with transfection technologies and for measuring gene expression and cells for facilitating gene editing and cell therapies; probes for scientific purposes; bioassay apparatus in the nature of instruments for use with transfection technologies and to facilitate gene editing and cell therapies; Laboratory instruments, namely, measuring apparatus for measuring gene expression and cells for facilitating gene editing and cell therapies for use in bioassay techniques and for use with transfection technologies, other than for medical use; parts and fittings for the aforesaid goods for use in conjunction with transfection technologies and instruments to facilitate gene editing and cell therapies for useACTIVE—
010Surgical, medical, and veterinary apparatus and instruments being used in the generation of cell therapies; medical and surgical probes; probes for medical use and medical diagnostic purposes; measuring apparatus and instruments for medical use, namely, for measuring gene expression and cells for facilitating gene editing and cell therapies for use in bioassay techniques and for use in conjunction with transfection technologies; parts and fittings for the aforesaidACTIVE—
042Scientific and technological services, namely, scientific research, analysis, testing in the field of cell therapy and research and design services relating thereto; industrial analysis and research services in the field of cell therapy; medical, scientific and pharmaceutical research and development, and clinical testing, in the field of pharmaceutical preparations, drugs, cell therapy, gene therapy and cancer therapy; development of probes, reagents and bioassays for industrial and scientific purposes; advisory, consultancy and information services relating to the provision of the aforesaidACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 16, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 16, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 16, 2026ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Oct 15, 2026GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Oct 15, 2026GNSLLETTER OF SUSPENSION E-MAILED—
Oct 15, 2026CNSLSUSPENSION LETTER WRITTEN—
Aug 27, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 27, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 27, 2026ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Aug 19, 2026GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Aug 19, 2026GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Aug 19, 2026CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jul 21, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 21, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 21, 2026TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 13, 2026GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 13, 2026GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 13, 2026CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 12, 2026DOCKASSIGNED TO EXAMINER—
Jun 11, 2026NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 12, 2026MAFRAPPLICATION FILING RECEIPT MAILED—
Feb 12, 2026NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance